Previous 10 | Next 10 |
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 26 th at 1:00 pm ET. A webcast of the presentation will be available ...
2023-08-22 18:25:08 ET More on Celldex Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU Celldex gains 12% on Phase 1 data for urticaria candidate Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder Celldex post...
2023-08-11 08:41:02 ET Summary Celldex Therapeutics focuses on developing and commercializing novel therapeutic candidates for various diseases, with a robust pipeline. The company's financials show a reduction in cash position but anticipate ample resources to cover operational c...
2023-08-08 17:15:17 ET Celldex press release ( NASDAQ: CLDX ): Q2 GAAP EPS of -$0.65 beats by $0.02 . Revenue of $0.27M (+68.8% Y/Y) misses by $0.39M . Cash, cash equivalents and marketable securities as of June 30, 2023 were $252.7 million compared to $278.4 m...
- Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 - - First patient dosed in Phase 2 EoE study - HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second qu...
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU). Barzolvolimab is a humaniz...
HAMPTON, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in eosinophilic esophagitis (EoE). EoE is the most common type of eosinophilic gastro...
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape - - At week 24, 55% of all patients with CSU in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose groups had complete response (UAS7) and 69% had wel...
HAMPTON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s barzolvolimab program will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023 being held June 9-11 in Ham...
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7 th at 9:00 am ET. A webcast of the presentation will be available on the " ...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that speci...
2024-05-09 23:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-07 18:15:02 ET Guggenheim analyst issues UNDERPERFORM recommendation for CLDX on May 7, 2024 04:00PM ET. The previous analyst recommendation was Underperform. CLDX was trading at $42.21 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...